This Software Stock Could Be a Big Winner From a COVID-19 Vaccine

This Software Stock Could Be a Big Winner From a COVID-19 Vaccine

Anaplan still looks cheap given its growth profile, the large industry it's disrupting, and the gradual reopening of the economy.